Mosunetuzumab (anti-CD20&CD3e) - Primary antibody, specific to MS4A1 & CD3E, Human IgG1, Antibody of CD20 (membrane-spanning 4-domains; subfamily A; member 1);Antibody of CD3e
Mosunetuzumab (anti-CD20&CD3e) - Primary antibody, specific to MS4A1 & CD3E, Human IgG1, Antibody of CD20 (membrane-spanning 4-domains; subfamily A; member 1);Antibody of CD3e
Antibody of CD20 (membrane-spanning 4-domains; subfamily A; member 1);Antibody of CD3e
Product Description
Mosunetuzumab (anti-CD20 & CD3e) is a full-length, fully humanized immunoglobulin G1 (IgG1) T-cell-dependent bispecific (TDB) antibody targeting CD20 (B cells) and CD3 (T cells). Mosunetuzumab (anti-CD20 & CD3e) redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs). Purity ≥90% (SDS-PAGE&SEC) Endotoxin Level ≤1.0EU/mg
Product Properties
Isotype
Human IgG1
Light Chain Type
kappa
SDS-PAGE
146.72 kDa
Purification Method
Protein A purified
Concentration
Lot by Lot
Storage Temp
Store at -80°C,Avoid repeated freezing and thawing
Shipped In
Ice chest + Ice pads
Stability And Storage
Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS
1905409-39-3
Images
Mosunetuzumab (anti-CD20&CD3e) (Ab175605) - Flow Cytometry Flow Cytometry analysis of Raji cells labelling CD20&CD3e (red) with Mosunetuzumab (anti-CD20&CD3e) (Ab175605) at 1.0 μg/mL for 1 hour at 4°C. Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Mosunetuzumab (anti-CD20&CD3e) (Ab175605) - Flow Cytometry Flow Cytometry analysis of Jurkat cells labelling CD20&CD3e (red) with Mosunetuzumab (anti-CD20&CD3e) (Ab175605) at 1.0 μg/mL for 1 hour at 4°C. Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Mosunetuzumab (anti-CD20&CD3e) (Ab175605) - SEC The purity of Mosunetuzumab (anti-CD20&CD3e) (Ab175605) is more than 95% verified by HPLC.
1.Sun LL, Ellerman D, Mathieu M, Hristopoulos M, Chen X, Li Y, Yan X, Clark R, Reyes A, Stefanich E et al.. (2015) Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies.. Sci Transl Med, 7 (287):(287ra70). [PMID:25972002][10.1021/op500134e]
2.Ferl GZ, Reyes A, Sun LL, Cheu M, Oldendorp A, Ramanujan S, Stefanich EG. (2018) A Preclinical Population Pharmacokinetic Model for Anti-CD20/CD3 T-Cell-Dependent Bispecific Antibodies.. Clin Transl Sci, 11 (3):(296-304). [PMID:29351372][10.1021/op500134e]
3.Hosseini I, Gadkar K, Stefanich E, Li CC, Sun LL, Chu YW, Ramanujan S. (2020) Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling.. NPJ Syst Biol Appl, 6 (1):(28). [PMID:32859946][10.1021/op500134e]
4.Budde LE, Assouline S, Sehn LH, Schuster SJ, Yoon SS, Yoon DH, Matasar MJ, Bosch F, Kim WS, Nastoupil LJ et al.. (2022) Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study.. J Clin Oncol, 40 (5):(481-491). [PMID:34914545][10.1021/op500134e]
5.Kang C. (2022) Mosunetuzumab: First Approval.. Drugs, 82 (11):(1229-1234). [PMID:35947358][10.1021/op500134e]
Solution Calculators
Molarity Calculator
Determine the necessary mass, volume, or concentration for preparing a solution.
Dilution Calculator
Determine the dilution needed to prepare a stock solution.
